Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04391569 · ClinicalTrials.gov registry record · Phase 3
Randomized Therapy In Status Epilepticus
A Phase 3 study, sponsored by Marinus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
NCT04391569 is a Phase 3 study that has completed, run by Marinus Pharmaceuticals. The registered enrollment target is 100 participants.
The verdict
NCT04391569, a Phase 3 study, has completed, sponsored by Marinus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
Study Summary
This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
Interventions
- DRUG Placebo
- DRUG Ganaxolone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-12-09 |
| Est. Completion | 2024-04-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04391569
The ClinicalTrials.gov registry entry for NCT04391569 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Marinus Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04391569 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04391569 about?
NCT04391569 is a clinical study titled "Randomized Therapy In Status Epilepticus". This study evaluated the effectiveness and safety of an investigational product (IP), intravenous (IV) ganaxolone, to treat participants with status epilepticus (SE).
What is the current status of trial NCT04391569?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2020-12-09. Estimated completion is 2024-04-28.
What interventions are being tested in trial NCT04391569?
The interventions under investigation include: Placebo (DRUG), Ganaxolone (DRUG).
Who is sponsoring clinical trial NCT04391569?
This trial is sponsored by Marinus Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.